Newsroom | Medtronic | 2017 Press Releases

2017 Press Releases


201720162015201420132012
Search News Releases
 
DateTitle  
11/21/17Medtronic Reports Second Quarter Financial Results
Revenue of $7.1 Billion; GAAP Diluted EPS of $1.48; Non-GAAP Diluted EPS of $1.07  Given Divestiture, Revenue Decreased 4% as Reported; Increased 3% at Comparable, Constant Currency or 4% Adjusting for Hurricane Maria Impact Company Reiterates Full Year Revenue and EPS Guidance DUBLIN - November 21, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2018, which ended October 27, 2017. The company reported second quarter worldwide rev... 
 Printer Friendly Version
11/20/17Medtronic Announces FDA Approval and U.S. Launch of Next Generation Pacemakers
Azure(TM) with BlueSync(TM) Technology Improves Device Longevity and Provides Automatic, Wireless Remote Patient Monitoring DUBLIN - November 20, 2017 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. commercial launch for its portfolio of Azure(TM) pacemakers with BlueSync(TM)technology. Available in both single chamber and dual chamber models, the Azure XT MRI and Azure S MRI pacemakers offer improved longevity, estimated at 13.7 years (dua... 
Download PDFPrinter Friendly Version
11/13/17Medtronic to Present New Clinical Data on Vascular Interventions and Key Symposia at VEITHsymposium 2017
DUBLIN - November 13, 2017 - Medtronic plc (NYSE: MDT) today announced several noteworthy presentations of clinical studies and symposia on aortic, peripheral, endoVenous, and vascular embolization therapies at the 44th Annual Symposium of Vascular and Endovascular Issues (VEITHsymposium), the world's largest educational meeting specializing in vascular surgical medicine in New York from November 14 - 18, 2017. In a first-to-podium presentation, William Jordan, M.D., professor of surgery and c... 
Download PDFPrinter Friendly Version
11/08/17Medtronic Announces Preliminary Second Quarter Revenue
Preliminary Revenue of Approximately $7.1 Billion Company Updates Hurricane Maria Impact to Second Quarter Financial Results Company Reiterates Second Quarter EPS Expectations Excluding Hurricane Maria Impact Second Quarter Financial Results to be Reported on November 21 DUBLIN - November 8, 2017 - Medtronic plc (NYSE: MDT) today announced its preliminary revenue for its second quarter of fiscal year 2018, which ended October 27, 2017. The company announced preliminary second quarter worldw... 
Download PDFPrinter Friendly Version
11/06/17Medtronic Receives CE Mark for the World's Smallest Fully Implantable Spinal Cord Stimulator and Announces European Launch of the Intellis Platform
New Neurostimulation System Is a Non-Opioid Alternative for Chronic Pain and Offers Personalized Pain Relief and Advanced Activity Tracking DUBLIN - November 6, 2017 - Medtronic plc (NYSE:MDT) today announced that it received CE (Conformité Européenne) Mark for the Intellis(TM) platform for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) as an aid in the management of certain types of chronic pain.* Intellis, the world's smallest fully implantable SCS neurostimulator, ... 
Download PDFPrinter Friendly Version
11/02/17Medtronic Releases Fiscal Year 2017 Integrated Performance Report
Report Highlights Company's Global Financial, Social, and Environmental Impact DUBLIN - November 2, 2017 - Medtronic plc (NYSE:MDT) announces the release of its fiscal year 2017 Integrated Performance Report. The report highlights the combined financial, social, and environmental impact of Medtronic. The FY2017 Integrated Performance Report details the company's commitment to addressing business and industry challenges. Based on the Global Reporting Initiative (GRI) G4 Guidelines, it's organiz... 
Download PDFPrinter Friendly Version
11/02/17Medtronic Evolut(TM) PRO TAVR System with Advanced Sealing Maintains Excellent Outcomes Over Time
Evolut PRO Valve Well-Positioned for Future with New Study Unveiled to Investigate Expanded Patient Population DUBLIN and DENVER - November 2, 2017 - Medtronic plc (NYSE:MDT) today presented new data at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting showcasing the excellent clinical performance of the Evolut(TM) Transcatheter Aortic Valve Replacement (TAVR) platform. Six-month data from the newest-generation Evolut PRO System demonstrated continued benefits of its unique valv... 
Download PDFPrinter Friendly Version
11/01/17Medtronic Unveils Strong Early Outcomes for the Intrepid(TM) Transcatheter Mitral Valve Replacement (TMVR) System
First Report Investigation at TCT Published in JACC Shows Substantial Mitral Valve Regurgitation Reductions and Versatility of Dual-Stent Design DUBLIN and DENVER - November 1, 2017 - Medtronic plc (NYSE:MDT) today presented positive data for its self-expanding Intrepid(TM) transcatheter mitral valve replacement (TMVR) system in patients with severe, symptomatic mitral valve regurgitation. Presented as a First Report Investigation at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Me... 
Download PDFPrinter Friendly Version
11/01/17Independent Study Shows New Data on Shortened DAPT in STEMI Patients with Medtronic Resolute Integrity Drug-Eluting Stent
DAPT-STEMI Late-Breaker at TCT Reveals Results of Shortened DAPT Duration in Higher-Risk Patients DUBLIN and DENVER - November 1, 2017 - Investigators today unveiled clinical data from the independently run DAPT-STEMI trial, which found no difference in patient outcomes between six-and 12-month dual anti-platelet therapy (DAPT) duration in ST-Elevation Myocardial Infarction (STEMI) patients implanted with the Resolute(TM) Integrity(TM) Drug-Eluting Stent (DES). The results help inform physicia... 
Download PDFPrinter Friendly Version
10/31/17New Analyses Reinforce Hemodynamic Benefits of Medtronic Evolut(TM) TAVR Platform in Intermediate Risk Aortic Stenosis Patients
Presented at TCT, Evolut TAVR Platform Showcases Positive Clinical Outcomes in Patients Wanting to Return to More Active Lives DUBLIN and DENVER - October 31, 2017 - Medtronic plc (NYSE:MDT) today presented new clinical research to support the positive clinical performance of the Evolut(TM) Transcatheter Aortic Valve Replacement (TAVR) Platform in intermediate-risk, severe, symptomatic, aortic stenosis patients. Outcomes from the Surgical Replacement and Transcatheter Aortic Valve Implantation ... 
Download PDFPrinter Friendly Version
10/25/17Medtronic Announces First Economic Analysis Demonstrating Benefits of Professional CGM in People with Type 2 Diabetes
DUBLIN - October 25, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced data from the first economic analysis conducted on the use of professional continuous glucose monitoring (CGM) in people with type 2 diabetes. Data from the study demonstrated significant cost avoidance to the healthcare system when used during a therapy change or when used at least twice per year. The results also reinforced the well-established clinical benefits of professional CGM us... 
Download PDFPrinter Friendly Version
10/23/17First Patient Treated in Landmark Transcatheter Mitral Valve Replacement (TMVR) Pivotal Trial
Global Medtronic APOLLO Trial Now Underway with the Intrepid(TM) TMVR System for Patients with Severe Mitral Regurgitation DUBLIN - October 23, 2017 - Medtronic plc (NYSE:MDT) today announced the first patient implant in the APOLLO Trial - the pivotal trial designed to evaluate the Intrepid(TM) TMVR system following receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA). As the first-ever pivotal trial for transcatheter mitral valve replacement the... 
Download PDFPrinter Friendly Version
10/16/17Medtronic Care Management Services and American Well Announce Strategic Partnership to Integrate Telehealth Capabilities
Partnership Focused on Enabling Care for Chronic, Co-Morbid Patients DUBLIN and BOSTON - October 16, 2017 - Medtronic plc (NYSE:MDT) today announced its Medtronic Care Management Services (MCMS) business and American Well® entered into a first-of-its-kind strategic partnership to enable a more complete telehealth solution focused on the unique needs of the complex, chronic, co-morbid patient population. Under the terms of the agreement, the businesses will work together to enable patient acces... 
 Printer Friendly Version
10/13/17Medtronic and Mercy Announce Data Sharing Partnership to Accelerate Medical Device Innovation
Real-World Clinical Data is Key to Creating More Effective Medical Devices and Enabling Better Patient Health DUBLIN and ST. LOUIS - October 13, 2017 - Medtronic plc (NYSE: MDT), the global leader in medical technology, and Mercy, the fifth largest Catholic health care system in the U.S., together will establish a new data sharing and analysis network that helps gather clinical evidence for medical device innovation and patient access. Traditional clinical trials can be complex, time consuming... 
 Printer Friendly Version
10/10/17Medtronic to Establish Innovation Center in Chengdu
Facilitating Clinical Training for Physicians and Advancing Local Healthcare Efficiency in Central and Western China DUBLIN and CHENGDU, Sichuan - October 10, 2017 - Medtronic plc (NYSE:MDT) today announced the groundbreaking of its Chengdu Innovation Center at the Singapore-Sichuan Hi-Tech Innovation Park in Sichuan Province. Set to open in 2020, this center will provide a leading, cross-disciplinary clinical training and research platform for medical workers in Sichuan and other central and w... 
Download PDFPrinter Friendly Version
10/09/17Medtronic Endurant(TM) II/IIs Stent Graft System Receives FDA Approval to Treat Short Neck Anatomies When Used with Heli-FX(TM) EndoAnchor(TM) System
New Indication Expands Treatment Options for AAA Patients with Hostile Neck Anatomy DUBLIN - October 9, 2017 - Medtronic plc (NYSE: MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the Endurant(TM) II/IIs stent graft system to treat abdominal aortic aneurysm (AAA) patients with neck lengths down to 4mm and <=60° infra-renal angulation when used in combination with the Heli-FX(TM) EndoAnchor(TM) system. The expanded indication enables the Endurant... 
Download PDFPrinter Friendly Version
10/06/17Medtronic Provides Update on Impact from Hurricane Maria
DUBLIN - October 6, 2017 - Medtronic plc (NYSE: MDT) today provided an update on the impact to its manufacturing and sales operations as a result of Hurricane Maria. All four of the company's business groups have some level of manufacturing across four major locations in Puerto Rico. Considering the severity of the hurricane, the company's Puerto Rico facilities fared well, but each sustained some damage. Medtronic has made considerable progress in repairing its Puerto Rico manufacturing facili... 
Download PDFPrinter Friendly Version
09/27/17Medtronic HeartWare(TM) HVAD(TM) System Approved for Destination Therapy
Patients with End-Stage Heart Failure Now Have New Options for Care DUBLIN - September 27, 2017 - Medtronic plc (NYSE: MDT) has received U.S. Food and Drug Administration (FDA) approval for its HeartWare(TM) HVAD(TM) System as a destination therapy for patients with advanced heart failure who are not candidates for heart transplants. The HVAD System, a left ventricular assist device or LVAD, helps the heart pump and increases the amount of blood that flows through the body. "LVADs are an ... 
 Printer Friendly Version
09/21/17Medtronic Announces Clinical Study to Evaluate the CoreValve(TM) Evolut(TM) PRO System in 'Everyday' Clinical Practice
New Study Designed to Assess Longer-Term Clinical Performance of Next-Generation Evolut PRO Transcatheter Aortic Valve Implantation (TAVI) System DUBLIN - September 21, 2017 - Medtronic plc (NYSE: MDT) today announced a new post-market clinical study to evaluate its CoreValve(TM) Evolut(TM) PRO valve in everyday clinical practice. Studying patients with severe symptomatic aortic stenosis at an intermediate, high or extreme risk for open heart surgery, the FORWARD PRO Clinical Study will evaluat... 
Download PDFPrinter Friendly Version
09/18/17Medtronic Announces FDA Approval and U.S. Launch of Next Generation Spinal Cord Stimulator for Chronic Pain Management
The Intellis Platform Includes the World's Smallest Implantable Spinal Cord Stimulator and  Offers Personalized Pain Relief and Advanced Activity Tracking DUBLIN - September 18, 2017 - Medtronic plc (NYSE:MDT) today announced FDA approval and U.S. launch of the Intellis(TM) platform for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems, such as battery performance, and can p... 
Download PDFPrinter Friendly Version
09/14/17Medtronic Announces Inaugural 2017 Global Champions Team
Athletes from Five Continents Benefitting from Medical Technology Will Showcase Remarkable Spirit at the Medtronic Twin Cities Marathon and Medtronic TC 10 Mile Events This October DUBLIN - September 14, 2017 - Long distance running is never easy. But for twenty long-distance runners participating in the Medtronic Twin Cities Marathon Weekend, just toeing the starting line is a remarkable achievement. This unique collection of athletes who benefit from medical technology will be honored as the... 
Download PDFPrinter Friendly Version
09/13/17New Five-Year Gender Subset Data from the Medtronic Engage Registry Presented in VIVA Late Breaking Trials
Five-Year, Real-World Data Demonstrate EVAR Outcomes with Endurant® II Stent Graft System Are Comparable in Both Male and Female Patients DUBLIN and LAS VEGAS - September 13, 2017 - Medtronic plc (NYSE: MDT) today reported its Endurant® II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability and consistent outcomes in a real-world setting among both male and female patients. The five-year ENGAGE global registry data were presented for the first time ... 
Download PDFPrinter Friendly Version
09/12/17Medtronic IN.PACT Admiral DCB Global Two Year Data and IN.PACT SFA Four Year Data Presented in VIVA Late Breaking Clinical Trials
Data Further Reinforce IN.PACT Admiral DCB as Frontline Option to Address Treatment Challenges in PAD DUBLIN and LAS VEGAS - September 12, 2017 - Medtronic plc (NYSE: MDT) data announced today reinforce the durability and safety of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The two-year, real-world results from the full clinical cohort of the IN.PACT Global Study and four-year results from the pivotal IN.PACT SFA Study were presente... 
Download PDFPrinter Friendly Version
09/12/17Medtronic Announces New StealthStation(TM) Technology for Ear, Nose, and Throat Procedures
New Platform to Offer Enhanced Visualization and Increased Efficiency for Surgery of the Sinuses and Skull Base DUBLIN - September 12, 2017 - Medtronic plc (NYSE: MDT) today announced the global launch of the StealthStation(TM) ENT, a new surgical navigation system designed for surgeons treating conditions within the ear, nose, and throat (ENT) anatomy. The company has received U.S. Food and Drug Administration 510k clearance and CE (Conformité Européenne) Mark for the system. StealthStation E... 
Download PDFPrinter Friendly Version
09/11/17Medtronic Announces Voluntary Recall of Diabetes Infusion Sets
DUBLIN - September 11, 2017 - Medtronic plc (NYSE:MDT) announced today that it has started to inform patients worldwide of a voluntary recall of specific lots of infusion sets used with all models of Medtronic insulin pumps. The recall is related to a certain discontinued component in these infusion sets and does not include insulin pumps or glucose sensors. The company determined, through recent field reports from patients and root cause analysis, that a component, the vent membrane, in the r... 
Download PDFPrinter Friendly Version
09/08/17Medtronic Announces Japanese Regulatory Approval for the IN.PACT(TM) Admiral(TM) Drug-Coated Balloon
Clinically-Proven, Durable, Consistent, and Safe Market-Leading DCB Poised to Improve Outcomes for PAD Patients in Japan DUBLIN - September 8, 2017 - Medtronic plc (NYSE: MDT) today announced that the IN.PACT(TM)Admiral(TM) Drug-Coated Balloon (DCB) received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of peripheral artery disease (PAD) in the upper leg - specifically, in the thigh (superficial femoral arteries (SFA)) and behind the knee (popliteal ... 
Download PDFPrinter Friendly Version
09/07/17Medtronic Chairman and CEO Omar Ishrak to Speak at Morgan Stanley Global Healthcare Conference
DUBLIN - September 7, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the 15th Annual Morgan Stanley Global Healthcare Conference on Monday, September 11, 2017, in New York City. Omar Ishrak, chairman and chief executive officer of Medtronic, will answer questions about the company beginning at 9:20 a.m. EDT (8:20 a.m. CDT). A live audio webcast of the presentation will be available on September 11, 2017, by clicking on th... 
Download PDFPrinter Friendly Version
09/07/17Medtronic Named Best Company to Work For in New Hampshire Fourth Year in a Row
PORTSMOUTH, N.H., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Medtronic (NYSE:MDT), a global medical device company with offices at the Pease Tradeport in Portsmouth, has been named the Best Company to Work For in New Hampshire for the fourth year in a row. The announcement was made last week by Business NH Magazine and is based on a judging process conducted with New Hampshire Businesses for Social Responsibility (NHBSR). Medtronic is featured in the magazine’s September issue, where the full list of ... 
Download PDFPrinter Friendly Version
09/07/17Medtronic Recognized for Its Sustainability Leadership
Company Marks a Decade on the North American Dow Jones Sustainability Index (DJSI) DUBLIN - September 7, 2017 - Medtronic plc (NYSE: MDT) was recognized today as one of the world's leading companies for sustainability with its ranking on the Dow Jones Sustainability North America Index (DJSI North America) for the tenth consecutive year. DJSI North America analyzes companies on a variety of sustainability criteria, including economic performance, environmental stewardship, social responsibility... 
Download PDFPrinter Friendly Version
09/05/17Medtronic EVP & CVG President Mike Coyle to Speak at Wells Fargo Healthcare Conference
DUBLIN - September 5, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the 2017 Wells Fargo Healthcare Conference on Thursday, September 7, 2017, in Boston. Mike Coyle, executive vice president and president of Medtronic's Cardiac and Vascular Group (CVG), will answer questions about the company beginning at 9:25 a.m. EDT (8:25 a.m. CDT). A live audio webcast of the presentation will be available on September 7, 2017, by cli... 
Download PDFPrinter Friendly Version
09/05/17Medtronic Launches Long Term Clinical Study Program of INFUSE Bone Graft in Two Common Spine Procedures: PLF and TLIF
First Patient Enrolled in Initial Posterolateral Fusion Study DUBLIN - September 5, 2017 - Medtronic plc (NYSE: MDT) today announced the launch of a long term clinical study program to collect prospective data on INFUSE® Bone Graft in Posterolateral Fusion (PLF) and Transforaminal Lumbar Interbody Fusion (TLIF) spine procedures. The first patient has been enrolled in the PLF study at Fort Wayne Orthopedics in Fort Wayne, Ind. The Spine team led by Dr. Kevin Rahn and Dr. Robert Shugart performed... 
Download PDFPrinter Friendly Version
08/28/17Medtronic Plans for Renal Denervation Pivotal Trial After New Study Shows Significant Blood Pressure Reductions
Published Simultaneously in The Lancet, the Late-Breaking SPYRAL HTN-OFF MED Study at ESC Successfully Isolates RDN Treatment Effect to Show Compelling Efficacy and Safety of Hypertension Procedure DUBLIN and BARCELONA - August 28, 2017 - Medtronic plc (NYSE:MDT) today announced its intent to move forward with a new renal denervation pivotal trial following positive first results from a sham-controlled study in patients with high blood pressure. Investigators of the SPYRAL HTN-OFF MED Study fo... 
Download PDFPrinter Friendly Version
08/25/17Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2018
DUBLIN - August 25, 2017 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2018 second quarter cash dividend of $0.46 per ordinary share, representing a 7 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2017. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 40 consecutive years. The dividend is p... 
Download PDFPrinter Friendly Version
08/22/17Medtronic Reports First Quarter Financial Results
Revenue of $7.390 Billion Grew 3% as Reported; 4% at Constant Currency  GAAP Diluted EPS of $0.74; Q1 Non-GAAP Diluted EPS of $1.12 GAAP Operating Margin Improved 250bps; Non-GAAP Operating Margin Improved 50bps at Constant Currency Company Reiterates Full Year Revenue and EPS Guidance DUBLIN - August 22, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2018, which ended July 28, 2017. The company reported first quarter worldwide ... 
Download PDFPrinter Friendly Version
08/21/17Medtronic Receives CE Mark for Attain Stability(TM) Quad MRI SureScan(TM) Active-Fixation Heart Lead
Clinical Trial Also Underway in U.S., Canada and Other Geographies DUBLIN - August 21, 2017 - Medtronic plc (NYSE: MDT) announced it has received CE (Conformité Européene) Mark for the Attain Stability(TM) Quad MRI SureScan(TM) left heart lead. Paired with Medtronic quadripolar cardiac resynchronization therapy-defibrillators (CRT-D) and -pacemakers (CRT-P), the Attain Stability Quad lead features novel, active-fixation technology that is designed for precise lead placement and stability. In t... 
Download PDFPrinter Friendly Version
08/17/17Medtronic EVP & CFO Karen L. Parkhill to Speak at Intellisight 2017 Conference
DUBLIN - August 17, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the CFA Society Minnesota's 6th Annual Investor Conference, Intellisight, on Wednesday, August 23, 2017, in Minneapolis. Karen Parkhill, executive vice president and chief financial officer of Medtronic, will make a presentation on the company beginning at 10:15 a.m. EDT (9:15 a.m. CDT). A live audio webcast of the presentation will be available on August 23, 201... 
Download PDFPrinter Friendly Version
08/15/17Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2018
DUBLIN - August 15, 2017 - Medtronic plc (NYSE: MDT) announced today that it will report financial results for the first quarter fiscal year 2018 on Tuesday, August 22, 2017. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for the company's first quarter of fiscal year 2018, which ended on Friday, July 28, 2017. Medtronic will host a webcast a... 
Download PDFPrinter Friendly Version
08/14/17Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology
First-of-its-Kind Randomized Clinical Trial Will Evaluate One-Month DAPT in Patients Following PCI Procedures with the Newer-Generation Durable Polymer Resolute Onyx DES DUBLIN- August 14, 2017 - Medtronic plc (NYSE: MDT) today announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT) - the combination of aspirin and an anti-clotting medication - in patients implanted with the Resolute Onyx(TM) Drug-Eluting Stent (DES) during percutaneous coronar... 
Download PDFPrinter Friendly Version
08/02/17Medtronic Expands Heart Valve Portfolio with FDA Approval and CE Mark of the Avalus(TM) Surgical Aortic Valve
Introduction of New Pericardial Aortic Heart Valve in the U.S. and Europe Reinforces Company's Commitment to Comprehensive Solutions to Heart Valve Disease DUBLIN - August 2, 2017 - Medtronic plc (NYSE: MDT) today announced CE (Conformité Européenne) mark and U.S. Food and Drug Administration (FDA) approval of its new Avalus(TM) pericardial aortic surgical valve for the treatment of aortic valve disease. The Avalus valve leverages proven surgical bioprosthetic valve concepts with added features... 
Download PDFPrinter Friendly Version
08/01/17FIRE AND ICE Trial Analysis Shows Medtronic Cryoballoon Reduces Healthcare System Costs and Utilization
Data from Landmark Trial Published in the Journal of the American Heart Association DUBLIN - August 1, 2017 - A new health economic analysis from the landmark FIRE AND ICE Trial, sponsored by Medtronic plc (NYSE: MDT), was published today in the Journal of the American Heart Association. The data show that treating paroxysmal atrial fibrillation (AF) with cryoballoon catheter ablation may result in substantial cost savings as compared to radiofrequency (RF) ablation. These findings were driven ... 
Download PDFPrinter Friendly Version
07/31/17Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing
DUBLIN - July 31, 2017 - Medtronic plc (NYSE:MDT) today announced CE (Conformité Européenne) mark and European launch of the CoreValve(TM)Evolut(TM) PRO valve for the treatment of severe aortic stenosis for symptomatic patients who are at intermediate, high or extreme risk for open heart surgery. Clinical data for the Evolut PRO valve was recently unveiled at the American College of Cardiology (ACC) 66th Annual Scientific Session, and showed high survival, low rates of stroke, minimal paravalvul... 
Download PDFPrinter Friendly Version
07/30/17Medtronic Completes Sale of a Portion of Its Patient Monitoring & Recovery Division to Cardinal Health
DUBLIN - July 30, 2017 - Medtronic plc (NYSE: MDT) today announced that it has completed the previously announced sale of its Patient Care, Deep Vein Thrombosis (Compression), and Nutritional Insufficiency businesses within the Patient Monitoring & Recovery (PMR) division of its Minimally Invasive Therapies Group (MITG) to Cardinal Health Inc. (NYSE: CAH) for $6.1 billion in cash. The company expects modest dilution on a net basis to its fiscal year 2018 non-GAAP earnings per share of approxim... 
Download PDFPrinter Friendly Version
07/17/17Five-Year Data Demonstrate InterStim(TM) Therapy Offers Sustained Long-Term Efficacy and Quality of Life Improvements for Overactive Bladder Patients
The InterStim System is the Only Proven, Long-Term Sacral Neuromodulation Solution for Overactive Active Bladder DUBLIN - July 17, 2017 - Medtronic plc (NYSE: MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of life improvements for overactive bladder (OAB) at five years.1 Results of the InSite study, which were published online in the Journal of Urology,1 found that 82 percent of patients had ther... 
Download PDFPrinter Friendly Version
07/11/17Clinical Trial to Evaluate Medtronic Cryoablation as First-Line Treatment for Patients With Symptomatic Paroxysmal Atrial Fibrillation
DUBLIN - July 11, 2017 - Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the safety and effectiveness of performing pulmonary vein isolation (PVI) with the Arctic Front Advance(TM) Cryoballoon in patients with symptomatic paroxysmal atrial fibrillation (AF) prior to treatment with antiarrhythmic medications. The first patient in the trial was recently enrolled at The Ohio State University Wexner Medical Center by Jaret Tyle... 
Download PDFPrinter Friendly Version
07/10/17Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval
Self-Expanding CoreValve(TM) Evolut(TM)TAVR Platform with Excellent Procedural Safety and Proven Valve Performance Helps Address Needs of Intermediate-Risk Patients DUBLIN - July 10, 2017 - Medtronic plc (NYSE: MDT) today announced the expanded U.S. Food and Drug Administration (FDA) approval of the self-expanding CoreValve(TM) Evolut(TM) transcatheter aortic valve replacement (TAVR) platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-h... 
Download PDFPrinter Friendly Version
06/28/17Medtronic SureTune(TM)3 Earns CE Mark for Deep Brain Stimulation Therapy
Data Presented at the 17th Quadrennial Meeting of the World Society for Stereotactic and Functional Neurosurgery in Berlin DUBLIN and BERLIN - June 28, 2017 - Medtronic plc (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for SureTune(TM)3 software for deep brain stimulation (DBS). SureTune3 provides patient-specific visualization of lead location and simulated volume of neural activation to help physicians make decisions on how to program - or tune - their patient's... 
Download PDFPrinter Friendly Version
06/26/17Medtronic Announces Outcomes-Based Agreement with Aetna for Type 1 and Type 2 Diabetes Patients
DUBLIN - June 26, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a new outcomes-based agreement with Aetna (NYSE:AET) for type 1 and type 2 diabetes patients currently on multiple daily insulin injections for their diabetes management. The agreement will measure health outcomes for those patients that choose to transition to pump therapy using a Medtronic insulin pump featuring SmartGuard(TM) Technology, including the new MiniMed(TM) 670G system* - the ... 
Download PDFPrinter Friendly Version
06/23/17Medtronic Announces 7 Percent Increase in Cash Dividend
40th Consecutive Year of Dividend Increases;Board Authorizes $5 Billion for Share Repurchases DUBLIN - June 23, 2017 - The board of directors of Medtronic plc (NYSE: MDT) today approved a 7 percent increase in its quarterly cash dividend, raising the quarterly amount to $0.46 per ordinary share. This would translate into an annual amount of $1.84 per ordinary share, or a dividend per share payout ratio of 40 percent of prior fiscal year non-GAAP diluted earnings per share. Today's announcement ... 
Download PDFPrinter Friendly Version
06/20/17New Data Reveal Medtronic CRT Devices Improve Therapy Delivery and Reduce Healthcare Costs
Data Presented at EUROPACE 2017 Reinforce Cost and Outcome Benefits of Exclusive EffectivCRT(TM) and AdaptivCRT(TM) Algorithms, Along with Improved Device Longevity DUBLIN and VIENNA - June 20, 2017 - Medtronic plc (NSYE: MDT) today announced new data showing that use of its cardiac resynchronization therapy (CRT) devices - with its proprietary AdaptivCRT(TM) and EffectiveCRT(TM) algorithms - results in lower healthcare system costs, and improves therapy delivery in heart failure patients who a... 
Download PDFPrinter Friendly Version
06/18/17Medtronic Exclusive Reactive ATP(TM) Therapy Slows Progression of Atrial Fibrillation in Real-World Patient Population
Data Presented as Late Breaking Clinical Trial at EUROPACE 2017 DUBLIN and VIENNA - June 18, 2017 - Continuing its leadership in the detection, reduction, and treatment of atrial fibrillation (AF), Medtronic plc (NYSE: MDT) today announced that its Reactive ATP(TM) therapy slows the progression of AF in patients with implanted cardiac devices. A robust, real-world analysis of nearly 8,800 patients was presented as a late breaking clinical trial at EHRA EUROPACE-CARDIOSTIM 2017. An unusually f... 
Download PDFPrinter Friendly Version
06/07/17Medtronic Initiates U.S. Launch of World's First Hybrid Closed Loop System for Type 1 Diabetes
The MiniMed(TM) 670G System Features the Company's Most Advanced SmartGuard(TM)HCL Technology and New Guardian(TM) Sensor 3 DUBLIN - June 7, 2017 - Medtronic plc (NYSE:MDT), today announced the U.S. launch of the MiniMed(TM) 670G system - the world's first Hybrid Closed Loop system for people with type 1 diabetes. Featuring the company's most advanced SmartGuard(TM) HCL technology and Guardian(TM) Sensor 3, it is the only insulin pump approved by the Food and Drug Administration (FDA) that ena... 
Download PDFPrinter Friendly Version
06/06/17Medtronic Announces Scientific Data Presentations at the American Diabetes Association 77th Meeting
Medtronic Will Host a Webcast of Its Diabetes Group Analyst and Investor Briefingon Saturday, June 10 from 2 - 4 p.m. PDT DUBLIN - June 6, 2017 - Medtronic (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the 77th Scientific Sessions of the American Diabetes Association, in San Diego, June 9-13. A significant portion of the scientific data being presented focuses on Medtronic's insulin pump systems, including the Mi... 
Download PDFPrinter Friendly Version
06/06/17Medtronic SureTune(TM)3 Receives Health Canada Licence for Deep Brain Stimulation Therapy
DUBLIN - June 6, 2017 - Medtronic plc (NYSE: MDT) today announced it has received a Health Canada licence for SureTune(TM)3 software for deep brain stimulation (DBS). The latest innovations in the SureTune technology allow for more precise, efficient treatment while also improving patient management with centralized data storage for easy reference. SureTune 3 provides patient-specific visualization of lead location and simulated volume of neural activation to help physicians make decisions on ho... 
Download PDFPrinter Friendly Version
05/31/17Medtronic Initiates PRODIGY - a Global Study to Identify Those at High Risk for Opioid Induced Respiratory Depression, a Preventable Form of Respiratory Compromise
DUBLIN - May 31, 2017 - Medtronic plc (NYSE: MDT) recently launched PRODIGY, a 1,650-patient global study, to identify individuals at high risk for opioid induced respiratory depression (OIRD), a form of respiratory compromise. It is the first study to assess the clinical and economic benefits derived from the use of pulse oximetry (a device that measures oxygen saturation and pulse rate) and capnography (a device that measures carbon dioxide in exhaled air and respiration rate), in patients rec... 
Download PDFPrinter Friendly Version
05/25/17Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results
Q4 Revenue of $7.9 Billion Grew 5% as Reported; 5% at Constant Currency  Q4 GAAP Diluted EPS of $0.84; Q4 Non-GAAP Diluted EPS of $1.33 FY17 Revenue of $29.7 Billion Grew 3% as Reported; Approximately 5% on a Constant Currency, Constant Week Basis FY17 GAAP Diluted EPS of $2.89; FY17 Non-GAAP Diluted EPS of $4.60 FY17 Cash Flow from Operations of $6.9 Billion; FY17 Free Cash Flow of $5.6 Billion DUBLIN - May 25, 2017 - Medtronic plc (NYSE: MDT) today announced financial... 
Download PDFPrinter Friendly Version
05/24/17Medtronic Enrolls First Patient in Study of IN.PACT(TM) AV Access Drug-Coated Balloon in Patients with End-Stage Renal Disease
DUBLIN - May 24, 2017 - Medtronic plc (NYSE: MDT) today announced that the first patient has been enrolled in the IN.PACT(TM) AV Access Drug-Coated Balloon (DCB) study for use in patients with end-stage renal disease (ESRD). The U.S. Food and Drug Administration (FDA) approved the investigational device exemption (IDE) study to evaluate the safety and efficacy of IN.PACT(TM) AV Access DCB as a treatment for failing arteriovenous (AV) fistulas in ESRD patients. "We are delighted to enroll a... 
Download PDFPrinter Friendly Version
05/24/17Medtronic Chairman and CEO Omar Ishrak to Speak at Goldman Sachs Global Healthcare Conference
DUBLIN - May 24, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the 38th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 13, 2017, in Rancho Palos Verdes, Calif. Omar Ishrak, chairman and chief executive officer of Medtronic, will answer questions about the company beginning at 10:40 a.m. PDT (12:40 p.m. CDT). A live audio webcast of the presentation will be available on June 13, 2017, by clicking on the... 
Download PDFPrinter Friendly Version
05/18/17Medtronic RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year
First-Ever Study on 2.0 mm DES, EuroPCR Late-Breaking Data Show Exceptional Deliverability and No Stent Thrombosis for the Resolute Onyx DES DUBLIN and PARIS- May 18, 2017 - Medtronic plc (NYSE: MDT) today announced that the Resolute Onyx(TM) Drug-Eluting Stent (DES) met its primary endpoint of Target Lesion Failure (TLF) at one year for the treatment of coronary artery disease in extra-small vessels. Results from the RESOLUTE ONYX 2.0 mm Clinical Study were presented today as a Hot Line/Late-B... 
Download PDFPrinter Friendly Version
05/17/17Medtronic Study Finds High Use of App-Based Remote Cardiac Monitoring Among Older Patients
Nearly 90 Percent of Patients 71 and Older Met Clinical Guidelines for Remote Monitoring DUBLIN and CHICAGO- May 17, 2017 - A new Medtronic plc (NYSE: MDT) study shows a high use of app-based remote cardiac monitoring among older patients. Presented at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions, the first-of-its-kind study evaluated 15,595 patients across 1,969 clinics with Medtronic pacemakers who were assigned a MyCareLink Smart(TM) app-based remote monitor... 
Download PDFPrinter Friendly Version
05/16/17Medtronic EVP & President Bryan Hanson to Speak at Jefferies 2017 Global Healthcare Conference
DUBLIN - May 16, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 2017 Jefferies Global Healthcare Conference on Thursday, June 8, 2017, in New York City. Bryan Hanson, executive vice president and president of Medtronic's Minimally Invasive Therapies Group, will answer questions about the company at 9:30 a.m. EDT (8:30 a.m. CDT). A live audio webcast of the session will be available on June 8, 2017, by clicking on the Invest... 
Download PDFPrinter Friendly Version
05/16/17New Data on CoreValve(TM) and Evolut(TM) R Self-Expanding TAVI Systems Show Excellent Clinical Outcomes in Routine Clinical Practice
Late-Breaking Real-World Study Results at EuroPCR from CoreValve ADVANCE and Evolut R FORWARD Registries Show Strong Performance Consistent with Data from CoreValve Randomized Clinical Trials DUBLIN and PARIS - May 16, 2017 - Medtronic plc (NYSE:MDT) today unveiled new positive data on the self-expanding CoreValve(TM) platform from the CoreValve ADVANCE and Evolut R FORWARD clinical studies - two large, rigorous global registries presented during Hot Line/Late-Breaking Clinical Trial Sessions a... 
Download PDFPrinter Friendly Version
05/15/17Data Reinforce Benefits of Medtronic Cardiac Resynchronization Therapy Technologies in 'Real-World' Setting
EffectivCRT(TM)and AdaptivCRT(TM) Exclusives Featured in Heart Rhythm 2017 Presentations DUBLIN - May 15, 2017 - Medtronic plc (NYSE: MDT) today announced new data supporting the clinical performance of the company's exclusive EffectivCRT(TM) Diagnostic and AdaptivCRT(TM) algorithm in heart failure patients who receive cardiac resynchronization therapy (CRT) devices. The data were recently presented at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions in Chicago. CR... 
Download PDFPrinter Friendly Version
05/12/17New Study Shows Medtronic Insertable Cardiac Monitors Detect High Rate of Atrial Fibrillation in Previously Undiagnosed High-Risk Patients
Results from the REVEAL AF Study Show That AF Would Have Gone Undetected in the Majority of Patients at High-Risk for AF and Stroke If Cardiac Monitoring Was Limited to 30 Days DUBLIN and CHICAGO - May 12, 2017 - Medtronic plc (NYSE: MDT) today announced results from a new clinical study showing Medtronic Insertable Cardiac Monitors (ICM) detected a high incidence of atrial fibrillation (AF) in patients previously undiagnosed but suspected to be at high-risk for AF and stroke. These data from t... 
Download PDFPrinter Friendly Version
05/11/17Medtronic Chairman and CEO Omar Ishrak to Speak at Bernstein Strategic Decisions Conference
DUBLIN - May 11, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the Bernstein 33rd Annual Strategic Decisions Conference on Friday, June 2, 2017, in New York City. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a presentation about the company beginning at 9:00 a.m. EDT (8:00 a.m. CDT). A live audio webcast of the presentation will be available on June 2, 2017, by clicking on the Investor Events ... 
Download PDFPrinter Friendly Version
05/11/17New Medtronic Study Reinforces Safety and Performance of the World's Smallest Pacemaker in a Real-World Patient Population
HRS Late-Breaking Trial Reveals High Implant Success Rate and Low Early Major Complication Rate for the Medtronic Micra® Transcatheter Pacing System (TPS) DUBLIN and CHICAGO - May 11, 2017 - Medtronic plc (NYSE: MDT) today announced preliminary results for the Medtronic Micra® Transcatheter Pacing System (TPS) Post-Approval Registry, revealing a 99.6 percent implant success rate and a low rate of major complications (1.51 percent) at 30 days in a diverse, real-world patient population. The stud... 
Download PDFPrinter Friendly Version
05/10/17Medtronic First to Receive FDA Approval for MR-Conditional Quadripolar Cardiac Resynchronization Therapy-Pacemakers
Portfolio of Next Generation Heart Failure Devices Offers Effective Pacing and Access to the Most Advanced Diagnostic Imaging Procedures DUBLIN - May 10, 2017 - Medtronic plc (NYSE:MDT) has received U.S. Food and Drug Administration (FDA) approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers (CRT-Ps) that improve therapy delivery for patients with heart failure. These devices also allow patients to receive MRI (magnetic resonance imaging) scans in either 1.5 or 3 ... 
Download PDFPrinter Friendly Version
05/09/17Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2017
DUBLIN - May 9, 2017 - Medtronic plc (NYSE: MDT) announced today that it will report financial results for the fourth quarter and fiscal year 2017 on Thursday, May 25, 2017. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for the company's fourth quarter and fiscal year 2017, which ended on Friday, April 28, 2017. Medtronic will host a webcast... 
Download PDFPrinter Friendly Version
05/01/17Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes
Engineered for Exceptional Deliverability, Advanced DES Technology Features Thinner Struts, Enhanced Visibility and the Broadest Size Matrix in the U.S. DUBLIN - May 1, 2017 - Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx(TM) Drug-Eluting Stent (DES). The Resolute Onyx DES builds on the proven clinical performance and superior deliverability of the Resolute Integrity(TM) DES to further strengthen the gold stan... 
Download PDFPrinter Friendly Version
04/26/17Five-Year Data from the Medtronic ENGAGE Registry Demonstrate Durable, Consistent, and Proven Outcomes in Real-World Setting
Presented at Charing Cross, Five-Year Clinical Data from Global ENGAGE Registry  Support Endurant II's Market-Leading Position Worldwide DUBLIN and LONDON - April 26, 2017 - Medtronic plc (NYSE:MDT) today reported its Endurant® II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability and consistent outcomes in a real-world setting. The five-year ENGAGE global registry data were presented for the first time at the 2017 Charing Cross Symposium in London... 
Download PDFPrinter Friendly Version
04/25/17New Medtronic Data Demonstrate Clinical and Quality of Life Benefits for VenaSeal Closure System in Venous Reflux Disease Patients
Three-Year VeClose Trial and One-Year WAVES Study Data Presented at Charing Cross DUBLIN and LONDON - April 25, 2017 - Medtronic plc (NYSE: MDT) today announced three-year outcomes from the VeClose U.S. pivotal clinical trial and one-year data from the WAVES study. Both results were presented by Kathleen Gibson, M.D., of Lake Washington Vascular in Bellevue, Wash., at the 2017 Charing Cross Symposium in London. The new data demonstrate the clinical and quality of life benefits of the Medtronic... 
Download PDFPrinter Friendly Version
04/25/17Medtronic Drug-Coated Balloon (DCB) Demonstrates Consistent Results in Two New Analyses of Complex PAD Patients
DUBLIN and LONDON - April 25, 2017 - Medtronic plc (NYSE: MDT) today reinforced consistent results for its IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) with two new sub-analyses from the IN.PACT Global Study in patients with peripheral artery disease (PAD). The new data were reported at the annual 2017 Charing Cross Symposium (CX) in London, one of the world's largest educational meetings specializing in vascular and endovascular disease management. Sub-Analysis in Patients with Complex Le... 
Download PDFPrinter Friendly Version
04/24/17Medtronic Announces Most Advanced StealthStation(TM) for Neurosurgery
New Platform to Offer Flexibility, Ease of Use, Improved Registration and Advanced Visualization for Custom Procedural Workflows   DUBLIN and LOS ANGELES - April 24, 2017 - Medtronic plc (NYSE:MDT) today launched its new StealthStation(TM) technology at the American Academy of Neurological Surgeons (AANS) annual conference in Los Angeles. StealthStation technology has been a mainstay in neurosurgery suites for the past 25 years, being used in more than 2.25 million procedures.   With the new St... 
 Printer Friendly Version
04/20/17Data Highlight Medtronic Vascular Innovations at Charing Cross 2017
New Data from the Global ENGAGE Registry, IN.PACT Admiral Global Study, and VeClose Study Among Key Presentations LONDON and DUBLIN - April 20, 2017 - Medtronic plc (NYSE: MDT) today announced key clinical studies for its leading vascular interventional portfolio will be featured at the annual 2017 Charing Cross Symposium (CX), one of the world's largest educational meetings specializing in vascular and endovascular disease management, in London from April 25-28, 2017. This year, more than 40 ... 
Download PDFPrinter Friendly Version
04/20/17Medtronic Brain Therapies Business Sponsors Parkinson's Unity Walk
DUBLIN - April 20, 2017 - Medtronic plc (NYSE: MDT) announced its sponsorship of the 23rd Parkinson's Unity Walk which will be held on April 22, 2017, in New York City. Beginning at 8:30 a.m. EDT, thousands of Parkinson's patients, caregivers and supporters will walk the 1.4 mile course through New York's Central Park. Medtronic will be on site at the Unity Walk to provide information on deep brain stimulation (DBS), a therapy that is shown to reduce some of the symptoms associated with Parkinso... 
Download PDFPrinter Friendly Version
04/18/17FDA Designates Medtronic Worldwide Voluntary Field Action on HVAD(TM) System Controllers and DC Adapters as Class I Recall
DUBLIN - April 18, 2017 - Medtronic plc (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has classified the company's recently initiated voluntary field action related to its HVAD(TM) System Controllers (serial numbers lower than CON300000) and DC Adapters (all serial numbers for product code 1435) as a Class I recall.   Medtronic began notifying clinicians outside of the United States in March 2017 about updated HVAD System Controllers and DC Adapters that were deve... 
Download PDFPrinter Friendly Version
04/18/17Medtronic Signs Definitive Agreement to Divest a Portion of Its Patient Monitoring & Recovery Division to Cardinal Health for $6.1 Billion
DUBLIN - April 18, 2017 - Medtronic plc (NYSE: MDT) today announced that it has entered into a definitive agreement with Cardinal Health Inc. (NYSE: CAH) to sell its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses within the Patient Monitoring & Recovery (PMR) division of its Minimally Invasive Therapies Group (MITG). The transaction is expected to close in Medtronic's second quarter of its fiscal year 2018, subject to receipt of customary regulatory approvals and sa... 
Download PDFPrinter Friendly Version
04/13/17Medtronic Syncs Garmin® Activity Tracker Data Directly into Remote Patient Monitoring Mobile Platform
Data from Garmin vívofit® Series Now Syncs to Medtronic Care Management Services NetResponse® Mobile Application to Help Track Patient Health at Home DUBLIN and OLATHE, Kan. - April 13, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, and Garmin International Inc., a unit of Garmin Ltd. (NASDAQ: GRMN), today announced the integration of Garmin wearable device data directly into Medtronic Care Management Services' (MCMS) remote patient monitoring platform. Medtronic was t... 
Download PDFPrinter Friendly Version
04/12/17Medtronic Seeks Runners from Around the World Benefitting from Medical Technology for 2017 Global Champions Team
Applications now open: www.medtronic.com/globalchampions Selected runners receive entry and travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October 2017 Up to 20 people will be selected for the 2017 Global Champions team DUBLIN - April 12, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced applications are now open for the 2017 Medtronic Global Champions team. Medtronic Global Champions is a new program that recognizes athletes... 
Download PDFPrinter Friendly Version
04/06/17Clinical Trial of Medtronic Heart Pump Delivers Positive Results with Less-Invasive Implant Procedure
HVAD(TM) System is a Mechanical Pump that Circulates Blood Throughout the Body in Patients with Advanced Heart Failure. DUBLIN and SAN DIEGO - April 6, 2017 - Preliminary results from the Medtronic plc (NYSE:MDT)-sponsored HVAD LATERAL(TM) study were presented today as a late breaking clinical trial during the 2017 International Society for Heart and Lung Transplantation (ISHLT) Scientific Meeting in San Diego. Patients with end-stage heart failure, who have not responded to standard medical man... 
Download PDFPrinter Friendly Version
04/06/17Medtronic Announces Voluntary Worldwide Recall of its StrataMR(TM) Adjustable Valves and Shunts
DUBLIN - April 6, 2017 - Medtronic plc (NYSE: MDT) today announced that on February 22, 2017 it notified customers of a voluntary recall of all unused units of the StrataMR(TM) adjustable valves and shunts. These products are manufactured and marketed by Medtronic's Neurosurgery business, which is part of the Brain Therapies division of the company's Restorative Therapies Group. This recall only applies to StrataMR adjustable valves and shunts and does not apply to Strata(TM) II or Strata(TM) NS... 
 Printer Friendly Version
04/05/17Study Shows Medtronic Left Ventricular Assist Devices Have Positive Results at One Year in Patients Seeking Long-Term LVAD Therapy
Data Presented in Late-Breaking Presentation at ISHLT 2017 DUBLIN and SAN DIEGO - April 5, 2017 - Medtronic plc (NYSE:MDT) today announced results of the ENDURANCE Supplemental trial in a late-breaking clinical trial session of the 2017 International Society for Heart and Lung Transplantation (ISHLT) Scientific Meeting in San Diego. The study evaluated the company's HVAD(TM) System as a destination (long-term) therapy for patients needing heart pumps (left ventricular assist devices, or LVAD) wh... 
Download PDFPrinter Friendly Version
04/05/17Medtronic Announces Worldwide Voluntary Field Corrective Action For Newport(TM) HT70 and Newport(TM) HT70 Plus Ventilators
DUBLIN - April 5, 2017 - Medtronic (NYSE: MDT) is notifying customers worldwide of a voluntary field corrective action for all its Newport HT70 and Newport HT70 Plus ventilators manufactured since 2010. The voluntary field corrective action is being conducted following reports that the ventilator may reset spontaneously during normal operation, without an accompanying alarm. The reported incidence of this condition is approximately one (1) reset in every seven million hours of ventilation. Follo... 
Download PDFPrinter Friendly Version
03/30/17Medtronic Initiates Global Trial Evaluating Cryoablation to Treat Persistent Atrial Fibrillation
DUBLIN - March 30, 2017 - Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP Persistent AF clinical trial. The trial will evaluate the safety and effectiveness of a pulmonary vein isolation-only (PVI) strategy for treating patients with persistent atrial fibrillation (AF), using the Arctic Front Advance(TM) Cardiac CryoAblation Catheter. John Harding, M.D., Doylestown Hospital in Doylestown, Penn., treated the first patient enrolled in the trial. STOP Persistent AF is a pr... 
Download PDFPrinter Friendly Version
03/24/17New Guidelines Support Use of Cardiac Monitoring for Patients with Unexplained Fainting
American College of Cardiology, American Heart Association and Heart Rhythm Society Jointly Issue First-Ever Syncope Guidelines that Reinforce Benefits of Continuous Cardiac Monitoring DUBLIN - March 24, 2017 - Newly published guidelines from the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Rhythm Society (HRS) recommend the use of cardiac monitors for evaluating patients with unexplained fainting, called syncope. The "2017 ACC/AHA/HRS Guideline... 
Download PDFPrinter Friendly Version
03/22/17Medtronic Receives FDA Approval for CoreValve(TM) Evolut(TM) Pro Transcatheter Valve with Advanced Sealing
First-Ever Data at ACC.17 Confirms Safety and Efficacy of New Self-Expanding, Recapturable Heart Valve at 30-Days with High Survival, Low Stroke and Minimal Paravalvular Leak DUBLIN - March 22, 2017 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve(TM) Evolut(TM) PRO valve for the treatment of severe aortic stenosis for symptomatic patients who are at high or extreme risk for open heart surgery. The approval comes on the... 
Download PDFPrinter Friendly Version
03/21/17Medtronic Announces Pricing of $2 Billion of Senior Notes
DUBLIN - March 21, 2017 - Medtronic plc (NYSE: MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), has priced an offering of $1,000,000,000 principal amount of 1.700 percent senior notes due 2019 and $850,000,000 principal amount of 3.350 percent senior notes due 2027 (collectively, the "notes"). All of Medtronic Luxco's obligations under the notes will be fully and unconditionally guaranteed by Medtronic plc and Medtro... 
Download PDFPrinter Friendly Version
03/17/17Landmark SURTAVI Clinical Trial Shows Transcatheter Aortic Valve Replacement (TAVR) with the Self-Expanding Platform Performs as Well as Surgery in Intermediate Risk Severe Aortic Stenosis Patients
Late-Breaking SURTAVI Pivotal Clinical Trial Presented at ACC.17 and Published in NEJM Meets Primary Endpoint at Two Years DUBLIN and WASHINGTON, D.C. - March 17, 2017 - Medtronic plc (NYSE: MDT) today unveiled first-ever clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, which was presented at the American College of Cardiology (ACC) 66th Annual Scientific Session and published simultaneously in The New England Journal of Medicine (NEJM)1. ... 
Download PDFPrinter Friendly Version
03/16/17Medtronic EVP & President Hooman Hakami to Speak at Oppenheimer Healthcare Conference
DUBLIN - March 16, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017, in New York City. Hooman Hakami, executive vice president and group president of Medtronic's Diabetes Group, will answer questions about the company beginning at 8:35 a.m. EDT (7:35 a.m. CDT). A live audio webcast of the presentation will be available on March 21, 2017, by clicking on t... 
Download PDFPrinter Friendly Version
03/15/17New Partnership Between Medtronic and Atlas General Hospital Brings Advanced Surgical Technologies and Treatment Options to Serbia
Partnership to Focus on Improving Quality and Accessibility of Spine Care for Serbian Patients BELGRADE, Serbia -  March 15, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the signing of an Integrated Health Solutions (IHS) agreement with Atlas General Hospital  in Belgrade, Serbia. With this partnership, both companies will contribute to the improvement of the care experiences of thousands of spine patients at the Atlas General Hospital. As part of i... 
 Printer Friendly Version
03/14/17Medtronic Melody Transcatheter Pulmonary Valve First of Its Kind to Receive FDA Approval for Implantation in Failed Surgical Pulmonary Heart Valves
Newly Approved Indication in U.S. Expands Treatment Options to More Patients with Congenital Heart Disease DUBLIN - March 14, 2017 - Medtronic plc (NYSE: MDT) today announced that its Melody(TM)Transcatheter Pulmonary Valve (TPV) received approval from the United States Food and Drug Administration (FDA) for implantation in patients whose surgical bioprosthetic pulmonary heart valves have failed. Designed specifically for the pulmonic position, Melody TPV is the first transcatheter pulmonary v... 
Download PDFPrinter Friendly Version
03/14/17Medtronic Announces New Bone Cement Indication for Treating Sacral Fractures
Minimally Invasive Procedure Provides More Options for Osteoporotic Fracture Patients Suffering from Pain DUBLIN - March 14, 2017 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of Kyphon(TM) Xpede Bone Cement for fixation of pathological fractures of the sacral vertebral body or ala using sacral vertebroplasty or sacroplasty - expanding the product's indications beyond treatment of vertebral fractures due to osteoporosi... 
Download PDFPrinter Friendly Version
03/13/17Medtronic Receives FDA Clearance for Reveal LINQ(TM) Insertable Cardiac Monitor (ICM) with TruRhythm(TM) Detection
Device Delivers Improved Accuracy and Streamlined Data for Clinicians DUBLIN - Mar. 13, 2017 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its Reveal LINQ(TM) Insertable Cardiac Monitor (ICM) with TruRhythm(TM) Detection, an advanced cardiac monitor offering improved accuracy to better identify abnormal heartbeats. Reveal LINQ ICM with TruRhythm Detection offers exclusive algorithms that result in a 95 percent reduction in false bradyc... 
Download PDFPrinter Friendly Version
03/10/17Medtronic Announces Medicare Reimbursement for the First and Only Leadless Pacemaker Available for Use in the U.S.
CMS Approves Required Studies for the Micra® Transcatheter Pacing System (TPS), the World's Smallest Pacemaker DUBLIN - Mar. 10, 2017 - Medtronic plc (NYSE: MDT) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has approved coverage for the Micra® Transcatheter Pacing System (TPS). This decision, effective immediately, follows the approval of two studies required to enable reimbursement through Medicare's policy of Coverage with Evidence Development (CED). In Janua... 
Download PDFPrinter Friendly Version
03/10/17Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2017
DUBLIN - Mar. 10, 2017 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2017 fourth quarter cash dividend of $0.43 per ordinary share, representing a 13 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2016.  Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 39 consecutive years. The dividend is p... 
Download PDFPrinter Friendly Version
03/09/17Medtronic Launches Below-The-Knee Clinical Study in Europe for Treatment of PAD Using New Drug-Coated Balloon Technology
First Procedure in Prospective, Randomized, Multi-Center Study Performed at Maria Cecilia Hospital in Italy DUBLIN - Mar. 9, 2017 - Medtronic plc (NYSE: MDT) today announced the launch of the IN.PACT(TM) BTK study to evaluate the effectiveness of using a drug-coated balloon (DCB) in patients with below-the-knee (BTK) peripheral arterial disease (PAD). This study will evaluate the IN.PACT 0.014 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter. This is an investigatio... 
Download PDFPrinter Friendly Version
03/03/17Medtronic EVP & CFO Karen L. Parkhill to Speak at Barclays Healthcare Conference
DUBLIN - Mar. 3, 2017 - Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Barclays Global Healthcare Conference on Wednesday, March 15, 2017, in Miami Beach, Florida. Karen Parkhill, executive vice president and chief financial officer of Medtronic, will make a presentation on the company beginning at 10:45 a.m. EDT (9:45 a.m. CDT). A live audio webcast of the presentation will be available on March 15, 2017, by clicking on the Inves... 
Download PDFPrinter Friendly Version
02/27/17New Analysis of Reverse Trial Shows Medtronic CRT Devices Cost-Effective, While Helping Patients with Mild Heart Failure Live Longer
JACC: HF Study Showcases Economic Value of Earlier Patient Access to Cardiac Resynchronization Therapy DUBLIN - Feb. 27, 2017 - Medtronic plc (NYSE:MDT) today announced an economic analysis of five-year data showing that patients with mild heart failure who get cardiac resynchronization therapy (CRT) devices early in their treatment live longer and that implanting these devices is cost-effective, compared to optimal medical therapy. Results from the REVERSE (REsynchronization reVErses Remodelin... 
Download PDFPrinter Friendly Version
02/27/17Medtronic EVP & RTG President Geoffrey S. Martha to Speak at Cowen Healthcare Conference
DUBLIN - Feb. 27, 2017 - Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 37th Annual Cowen and Company Healthcare Conference on Tuesday, March 7, 2017, in Boston, Mass. Geoff Martha, executive vice president and president of the Medtronic Restorative Therapies Group (RTG), will answer questions about the company beginning at 8:40 a.m. EST (7:40 a.m. CST). A live audio webcast of the presentation will be available on March 7, 2017, ... 
Download PDFPrinter Friendly Version
02/24/17Medtronic Receives CE Mark for Its Next Generation Cardiac Resynchronization Therapy-Pacemakers
Suite of Smart Heart Failure Devices Offers More-Effective Pacing, Expanded MRI Access DUBLIN - Feb. 24, 2017 - Medtronic plc (NYSE:MDT) today announced that it has received CE (Conformité Européenne) Mark for a suite of quadripolar cardiac resynchronization therapy pacemakers (CRT-Ps) that also allow patients to receive MRI (magnetic resonance imaging) scans in either 1.5 or 3 Tesla (T) machines. This complete line of CRT-Ps, available in Europe in March, includes the Percepta(TM) Quad CRT-P M... 
Download PDFPrinter Friendly Version
02/23/17New Solitaire(TM) Stent Retriever Study Validates Outcomes and Real-World Application of Stroke Treatment Best Practices
Economic Study Finds Solitaire Stent Retriever Highly Cost-Effective DUBLIN and HOUSTON - Feb. 23, 2017 - Data presented today on Medtronic's (NYSE:MDT) Solitaire stent retriever at the International Stroke Conference (ISC) in Houston demonstrate that the results from the four pivotal randomized controlled trials - SOLITAIRE(TM) FR With the Intention For Thrombectomy as PRIMary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME), Endovascular Treatment for Small Core and Proximal Occ... 
Download PDFPrinter Friendly Version
02/21/17Medtronic Reports Third Quarter Financial Results
Revenue of $7.3 Billion Grew 5% as Reported; 6% at Constant Currency GAAP Diluted EPS of $0.59; Non-GAAP Diluted EPS of $1.12 GAAP Diluted EPS Declined 23%; Non-GAAP EPS Grew 10% at Constant Currency GAAP Operating Margin Declined 380 bps; Non-GAAP Operating Margin Improved 130 bps at Constant Currency GAAP Cash Flow from Operations of $2.1 Billion; Free Cash Flow of $1.8 Billion DUBLIN - February 21, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its third qua... 
Download PDFPrinter Friendly Version
02/17/17Medtronic Announces Japanese Regulatory Approval for Micra(TM) Transcatheter Pacing System (TPS)
DUBLIN - Feb. 17, 2017 - Medtronic plc (NYSE: MDT) today announced Japan regulatory approval for the world's smallest pacemaker, the Micra(TM) Transcatheter Pacing System (TPS). Japan's Pharmaceuticals and Medical Device Agency (PMDA) granted approval for Micra based on positive data from the Medtronic Micra TPS Global Clinical Trial, which enrolled 744 patients and evaluated the safety and efficacy of the device through a single-arm, multi-center study at 56 centers in 19 countries, including J... 
Download PDFPrinter Friendly Version
02/16/17FDA Approves Expanded Indication for Medtronic Freezor® Xtra Cryoablation Catheter
Demonstrated Safe and Effective for Treating Patients with Abnormal Heart Rhythm of AVNRT DUBLIN - Feb. 16, 2017 - Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) has approved its Freezor® Xtra Cryoablation Catheter for treating patients with atrioventricular nodal re-entrant tachycardia (AVNRT), a life-threatening abnormal heart rhythm. The Freezor Xtra Catheter is a flexible, single-use device used to freeze cardiac tissue and block unnecessary electrical... 
Download PDFPrinter Friendly Version
02/16/17Medtronic Introduces Signia(TM) Stapling System, Innovative Surgical Stapler for Minimally Invasive Surgery
New Single-Handed Powered Stapling System Provides Real-time Feedback During Surgery1 DUBLIN - Feb. 16, 2017 - Delivering on its commitment to develop and expand minimally invasive surgery (MIS) technologies and capabilities, Medtronic plc (NYSE: MDT) announced the launch of its Signia(TM) Stapling System. The latest addition to the company's MIS portfolio, the Signia system provides surgeons with real-time feedback and automated responses to that real-time data. The Signia system includes Ada... 
Download PDFPrinter Friendly Version
02/15/17Medtronic's OsteoCool(TM) RF Ablation System Receives Expanded Indication for Palliative Treatment of Metastatic Bone Tumors
Minimally-Invasive Procedure Is First of its Kind in the U.S. to Bring Relief to Patients Suffering from Metastatic Bone Tumors DUBLIN - Feb. 15, 2017 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded indication for the OsteoCool(TM) RF Ablation System. Originally cleared for use in the spine, the FDA now allows the marketing of the OsteoCool System for palliative treatment of metastases in all bony anatomy - such as ribs, sacr... 
Download PDFPrinter Friendly Version
02/13/17Medtronic EVP & President Michael J. Coyle to Speak at RBC Capital Markets Global Healthcare Conference
DUBLIN - Feb. 13, 2017 - Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced it will participate in the RBC Capital Markets 2017 Global Healthcare Conference on Thursday, February 23, 2017, in New York City. Mike Coyle, executive vice president and president of Medtronic's Cardiac and Vascular Group, will answer questions about the company, beginning at 10:30 a.m. EST (9:30a.m. CST). A live audio webcast of the presentation will be available on February 23, 2017... 
Download PDFPrinter Friendly Version
02/13/17Medtronic Expands Coronary Portfolio to Include New DxTerity(TM) Diagnostic Catheters and Suite of Tools for the Transradial Approach
Full Line of Innovative Transradial Products and Comprehensive Training Programs Reinforce Medtronic's Commitment to Optimizing the Treatment of Heart Disease DUBLIN - Feb. 13, 2017 - Medtronic plc (NYSE: MDT) today announced that its market-leading coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line and several transradial-specific products including the DxTerity TRA(TM), InTRAkit(TM) access kit and TRAcelet(TM) compression device, all of which received U.S. F... 
Download PDFPrinter Friendly Version
02/13/17Medtronic Announces New, Outcome-Based Learning Program
Introduces New Approach to Healthcare Education and Development Focused on Outcomes That Matter to Patients DUBLIN - Feb. 13, 2017 - Medtronic today announced the launch of Medtronic Impact in its Europe, Middle East & Africa region, which is part of the company's drive towards value-based healthcare (VBHC). Medtronic Impact introduces an entirely new approach to healthcare education and development, extending beyond traditional product and procedure training to delivering learning based ... 
Download PDFPrinter Friendly Version
02/10/17Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2017
DUBLIN - Feb. 10, 2017 - Medtronic plc (NYSE: MDT) announced today that it will report financial results for its third quarter of fiscal year 2017 on Tuesday, February 21, 2017. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for the company's third quarter of fiscal year 2017, which ended on Friday, January 27, 2017. Medtronic will host a webc... 
Download PDFPrinter Friendly Version
02/09/17First Drug-Coated Balloon (DCB) Study Results in Japan Demonstrate Consistent Clinical Outcomes with Other Medtronic DCB Studies
New Data Recently Presented at LINC 2017 Represents the First Presentation of Clinical Results Comparing a DCB to Angioplasty in Japan DUBLIN - Feb. 9, 2017 - Medtronic plc (NYSE: MDT) today announced the one-year clinical outcomes from the MDT-2113 IN.PACT SFA Japan Trial. The data was recently presented by Osamu Iida, M.D., Kansai Rosai Hospital, Hyogo, Japan at the Leipzig Interventional Course (LINC) 2017 conference, and reinforced the consistent clinical outcomes obtained using Medtronic'... 
Download PDFPrinter Friendly Version
02/06/17Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors
Contract Award Continues Medtronic Care Management Services Veteran Support Initiated in 2011 DUBLIN - Feb. 6, 2017 - Medtronic plc (NYSE:MDT) today announced Medtronic Care Management Services (MCMS) is one of four vendors awarded a national contract from the U.S. Department of Veterans Affairs (VA) for Home Telehealth Technologies. MCMS has supplied the VA with telehealth solutions since 2011, and the new contract enables MCMS to continue supplying the VA with innovative remote patient monito... 
Download PDFPrinter Friendly Version
02/01/17Medtronic CardioInsight Mapping Solution Cleared by FDA
System First Used Commercially in U.S. This Week DUBLIN - Feb. 1, 2017 - Medtronic plc (NYSE: MDT) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the CardioInsight(TM) Noninvasive 3D Mapping System. The CardioInsight system is used to map a wide range of irregular heart rhythms in the upper and lower chambers of the heart, and provides electroanatomic 3D maps of the heart. The system was first used commercially in the U.S. by Vivek Reddy, M.D., director of cardiac arrh... 
Download PDFPrinter Friendly Version
01/26/17Medtronic Announces Medicare Coverage Decision for the First and Only Leadless Pacemaker Available for Use in the U.S.
CMS Decision Expands Patient Access to the Micra® Transcatheter Pacing System (TPS), the World's Smallest Pacemaker DUBLIN - Jan. 26, 2017 - Medtronic plc (NYSE: MDT) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) will cover leadless cardiac pacemakers, as outlined in the agency's final National Coverage Determination (NCD). This decision will provide Medicare patient access to leadless pacemakers, consistent with the FDA-approved labeling for the devices, throug... 
Download PDFPrinter Friendly Version
01/26/17Medtronic Receives IDE Approval to Initiate Study of IN.PACT® Admiral® Drug-Coated Balloon for a New Indication in Patients with End-Stage Renal Disease
DUBLIN - Jan. 26, 2017 - Medtronic plc (NYSE: MDT) today announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) to initiate a study of the IN.PACT® Admiral® drug-coated balloon (DCB) for a potential new indication in patients with end-stage renal disease. The randomized study will evaluate the IN.PACT Admiral DCB as a treatment for failing arteriovenous (AV) fistulas in these patients as compared to plain balloon angioplasty. The IDE appro... 
Download PDFPrinter Friendly Version
01/25/17Medtronic IN.PACT Admiral Drug-Coated Balloon Demonstrates Consistent Results in Asia and Belgium According to New Data Presented at LINC 2017
First Presentation of Results from Regional Cohorts of IN.PACT Global Study Reinforce Strong, Consistent and Safe Outcomes for PAD Patients  DUBLIN and LEIPZIG, Germany - Jan. 25, 2017 - Medtronic today presented new data at the Leipzig Interventional Course (LINC) 2017 conference supporting the IN.PACT® Admiral® drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The real-world outcomes from regional cohorts of the IN.PACT Global Study in Asia and Belgium reinforce the... 
Download PDFPrinter Friendly Version
01/24/17First Procedure Performed in Medtronic MRI-Guided Laser Ablation Trial to Treat Common Form of Epilepsy
DUBLIN - Jan. 24, 2017 - Medtronic plc (NYSE: MDT) announced today that the first procedure using the Visualase(TM) MRI-Guided Laser Ablation System has been performed in the pivotal SLATE (Stereotactic Laser Ablation for Temporal Lobe Epilepsy) clinical trial at Mayo Clinic in Rochester, Minn. The SLATE clinical trial is designed to support the expanded indication of the currently marketed Visualase(TM) system for treatment of patients with drug-resistant mesial temporal lobe epilepsy (MTLE), t... 
Download PDFPrinter Friendly Version
01/24/17Medtronic Announces CE Mark for New Lower Profile HawkOne 6F Directional Atherectomy System
Expands Treatment Options for Patients in Europe with Peripheral Artery Disease Both Above and Below the Knee DUBLIN - Jan. 24, 2017 - Medtronic plc (NYSE: MDT) today announced CE (Conformité Européene) Mark approval for the HawkOne(TM) directional atherectomy system in a lower profile size for treating patients with peripheral artery disease (PAD). The new HawkOne 6 French (6F) provides an effective and easy-to-use treatment option for patients with PAD both above and below the knee with a si... 
Download PDFPrinter Friendly Version
01/17/17Medtronic Announces CE Mark and European Launch of Recaptureable TAVI System Now Available for Severe Aortic Stenosis Patients with Large Anatomies
Larger Device Offers Treatment to Patients Without a Previous TAVI Option DUBLIN - Jan. 17, 2017 - Medtronic plc (NYSE:MDT) today announced the CE (Conformité Européenne) mark and European launch of the CoreValve(TM) Evolut(TM) R 34 mm valve-the largest sized transcatheter aortic valve implantation (TAVI) system available in Europe. The new Evolut R 34 mm valve is approved for severe aortic stenosis patients who are at intermediate, high or extreme risk for surgery with an annulus size ranging ... 
Download PDFPrinter Friendly Version
01/03/17Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference
DUBLIN - Jan. 3, 2017 - Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017, in San Francisco.  Omar Ishrak, chairman and chief executive officer of Medtronic, will make a formal presentation on the company beginning at 10:00 a.m. PST (12:00 p.m. CST).  Shortly following the presentation, Ishrak and Karen Parkhill, executive vice president and chief financial offic... 
Download PDFPrinter Friendly Version
X